Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives $3.75 Consensus PT from Analysts

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) have been assigned an average recommendation of “Hold” from the seven ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $3.75.

HOWL has been the topic of several research analyst reports. Citigroup lowered Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a report on Friday, December 19th. HC Wainwright decreased their target price on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, December 19th. Citizens Jmp cut shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, December 19th. Zacks Research cut shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 21st. Finally, Bank of America decreased their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th.

Werewolf Therapeutics Price Performance

Shares of Werewolf Therapeutics stock opened at $0.81 on Friday. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics has a twelve month low of $0.53 and a twelve month high of $2.38. The business has a 50-day moving average price of $0.65 and a 200 day moving average price of $1.06. The firm has a market cap of $39.37 million, a PE ratio of -0.50 and a beta of 0.78.

Insiders Place Their Bets

In related news, Director Luke Evnin sold 108,606 shares of the firm’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $0.61, for a total value of $66,249.66. Following the transaction, the director directly owned 2,550,674 shares of the company’s stock, valued at approximately $1,555,911.14. This trade represents a 4.08% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders have sold 692,080 shares of company stock valued at $427,177. Company insiders own 23.60% of the company’s stock.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of hedge funds have recently made changes to their positions in HOWL. Jane Street Group LLC acquired a new stake in shares of Werewolf Therapeutics in the second quarter worth approximately $409,000. Renaissance Technologies LLC raised its stake in Werewolf Therapeutics by 48.6% in the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after purchasing an additional 221,766 shares during the last quarter. Citadel Advisors LLC purchased a new position in Werewolf Therapeutics in the 3rd quarter valued at $304,000. Vanguard Group Inc. lifted its holdings in Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after purchasing an additional 109,796 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in Werewolf Therapeutics during the 2nd quarter worth $113,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.